Research ExplorerPublicationsCytoplasmic accumulation of ELAVL1 is an independent predict...

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer

Standard

Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. / Melling, Nathaniel; Taskin, B; Hube-Magg, Claudia; Kluth, Martina; Minner, Sarah; Koop, Christina; Grob, Tobias; Graefen, Markus; Heinzer, Hans; Tsourlakis, Maria Christina; Izbicki, Jakob; Wittmer, Corinna; Huland, Hartwig; Simon, Ronald; Wilczak, Waldemar; Sauter, Guido; Steurer, Stefan; Schlomm, Thorsten; Krech, Till.

In: PROSTATE, Vol. 76, No. 3, 02.2016, p. 259-72.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Melling, N, Taskin, B, Hube-Magg, C, Kluth, M, Minner, S, Koop, C, Grob, T, Graefen, M, Heinzer, H, Tsourlakis, MC, Izbicki, J, Wittmer, C, Huland, H, Simon, R, Wilczak, W, Sauter, G, Steurer, S, Schlomm, T & Krech, T 2016, 'Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer', PROSTATE, vol. 76, no. 3, pp. 259-72. https://doi.org/10.1002/pros.23120

APA

Melling, N., Taskin, B., Hube-Magg, C., Kluth, M., Minner, S., Koop, C., Grob, T., Graefen, M., Heinzer, H., Tsourlakis, M. C., Izbicki, J., Wittmer, C., Huland, H., Simon, R., Wilczak, W., Sauter, G., Steurer, S., Schlomm, T., & Krech, T. (2016). Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. PROSTATE, 76(3), 259-72. https://doi.org/10.1002/pros.23120

Vancouver

Melling N, Taskin B, Hube-Magg C, Kluth M, Minner S, Koop C et al. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. PROSTATE. 2016 Feb;76(3):259-72. https://doi.org/10.1002/pros.23120

Bibtex

@article{ab32b5eb758a47ec81643794f6d94ebd,
title = "Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer",
abstract = "BACKGROUND: ELAVL1 is an RNA binding protein involved in translation control, which might have a regulatory role in prostate cancer progress.METHODS: To evaluate its impact and relationship with key genomic alterations, ELAVL1 expression was analyzed by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers.RESULTS: The analysis revealed a mild to moderate predominantly nuclear immunostaining in normal prostate epithelium and an often higher both cytoplasmic and nuclear expression in cancer cells. Weak, moderate, and strong cytoplasmic ELAVL1 staining was found in 43%, 18%, and 3% of 10,478 interpretable tumors. Strong ELAVL1 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal status, and PSA recurrence (P < 0.0001 each). A combined analysis of the effect of nuclear and cytoplasmic ELAVL1 expression on PSA recurrence revealed that the association with patient outcome was entirely driven by cytoplasmic staining. ELAVL1 positivity was more frequent in cancers harboring TMPRSS2:ERG fusions found by FISH (78%) or showing immunohistochemical ERG expression (74%) than in cancers without ERG rearrangement (63%) or ERG expression (58%, P < 0.0001 each). Strong cytoplasmic ELAVL1 staining was further linked to presence of PTEN, 5q21, 6q15, and 3p13 deletions (P < 0.0001 each), an observation consistent with cytoplasmic ELAVL1 accumulation in case of genomic instability. The prognostic role of ELAVL1 expression was independent of Gleason grade, T stage, N stage, surgical margin status, and preoperative PSA, irrespective of whether preoperative or postoperative variables were used for modeling.CONCLUSION: Our study identifies cytoplasmic accumulation of ELAVL1 as a predictor of adverse clinical behavior of prostate cancer independent of established clinico-pathological parameters. Prostate 76:259-272, 2016. {\textcopyright} 2015 Wiley Periodicals, Inc.",
author = "Nathaniel Melling and B Taskin and Claudia Hube-Magg and Martina Kluth and Sarah Minner and Christina Koop and Tobias Grob and Markus Graefen and Hans Heinzer and Tsourlakis, {Maria Christina} and Jakob Izbicki and Corinna Wittmer and Hartwig Huland and Ronald Simon and Waldemar Wilczak and Guido Sauter and Stefan Steurer and Thorsten Schlomm and Till Krech",
note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",
year = "2016",
month = feb,
doi = "10.1002/pros.23120",
language = "English",
volume = "76",
pages = "259--72",
journal = "PROSTATE",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer

AU - Melling, Nathaniel

AU - Taskin, B

AU - Hube-Magg, Claudia

AU - Kluth, Martina

AU - Minner, Sarah

AU - Koop, Christina

AU - Grob, Tobias

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Tsourlakis, Maria Christina

AU - Izbicki, Jakob

AU - Wittmer, Corinna

AU - Huland, Hartwig

AU - Simon, Ronald

AU - Wilczak, Waldemar

AU - Sauter, Guido

AU - Steurer, Stefan

AU - Schlomm, Thorsten

AU - Krech, Till

N1 - © 2015 Wiley Periodicals, Inc.

PY - 2016/2

Y1 - 2016/2

N2 - BACKGROUND: ELAVL1 is an RNA binding protein involved in translation control, which might have a regulatory role in prostate cancer progress.METHODS: To evaluate its impact and relationship with key genomic alterations, ELAVL1 expression was analyzed by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers.RESULTS: The analysis revealed a mild to moderate predominantly nuclear immunostaining in normal prostate epithelium and an often higher both cytoplasmic and nuclear expression in cancer cells. Weak, moderate, and strong cytoplasmic ELAVL1 staining was found in 43%, 18%, and 3% of 10,478 interpretable tumors. Strong ELAVL1 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal status, and PSA recurrence (P < 0.0001 each). A combined analysis of the effect of nuclear and cytoplasmic ELAVL1 expression on PSA recurrence revealed that the association with patient outcome was entirely driven by cytoplasmic staining. ELAVL1 positivity was more frequent in cancers harboring TMPRSS2:ERG fusions found by FISH (78%) or showing immunohistochemical ERG expression (74%) than in cancers without ERG rearrangement (63%) or ERG expression (58%, P < 0.0001 each). Strong cytoplasmic ELAVL1 staining was further linked to presence of PTEN, 5q21, 6q15, and 3p13 deletions (P < 0.0001 each), an observation consistent with cytoplasmic ELAVL1 accumulation in case of genomic instability. The prognostic role of ELAVL1 expression was independent of Gleason grade, T stage, N stage, surgical margin status, and preoperative PSA, irrespective of whether preoperative or postoperative variables were used for modeling.CONCLUSION: Our study identifies cytoplasmic accumulation of ELAVL1 as a predictor of adverse clinical behavior of prostate cancer independent of established clinico-pathological parameters. Prostate 76:259-272, 2016. © 2015 Wiley Periodicals, Inc.

AB - BACKGROUND: ELAVL1 is an RNA binding protein involved in translation control, which might have a regulatory role in prostate cancer progress.METHODS: To evaluate its impact and relationship with key genomic alterations, ELAVL1 expression was analyzed by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers.RESULTS: The analysis revealed a mild to moderate predominantly nuclear immunostaining in normal prostate epithelium and an often higher both cytoplasmic and nuclear expression in cancer cells. Weak, moderate, and strong cytoplasmic ELAVL1 staining was found in 43%, 18%, and 3% of 10,478 interpretable tumors. Strong ELAVL1 staining was linked to high Gleason grade, advanced pathological tumor stage, positive nodal status, and PSA recurrence (P < 0.0001 each). A combined analysis of the effect of nuclear and cytoplasmic ELAVL1 expression on PSA recurrence revealed that the association with patient outcome was entirely driven by cytoplasmic staining. ELAVL1 positivity was more frequent in cancers harboring TMPRSS2:ERG fusions found by FISH (78%) or showing immunohistochemical ERG expression (74%) than in cancers without ERG rearrangement (63%) or ERG expression (58%, P < 0.0001 each). Strong cytoplasmic ELAVL1 staining was further linked to presence of PTEN, 5q21, 6q15, and 3p13 deletions (P < 0.0001 each), an observation consistent with cytoplasmic ELAVL1 accumulation in case of genomic instability. The prognostic role of ELAVL1 expression was independent of Gleason grade, T stage, N stage, surgical margin status, and preoperative PSA, irrespective of whether preoperative or postoperative variables were used for modeling.CONCLUSION: Our study identifies cytoplasmic accumulation of ELAVL1 as a predictor of adverse clinical behavior of prostate cancer independent of established clinico-pathological parameters. Prostate 76:259-272, 2016. © 2015 Wiley Periodicals, Inc.

U2 - 10.1002/pros.23120

DO - 10.1002/pros.23120

M3 - SCORING: Journal article

C2 - 26764246

VL - 76

SP - 259

EP - 272

JO - PROSTATE

JF - PROSTATE

SN - 0270-4137

IS - 3

ER -